Thrombolytics in acute ischaemic stroke: Historical perspective and future opportunities

Cerebrovascular Diseases

Volumn 35, Issue 4, 2013, Pages 313-319

  Röther, Joachim ^a   Ford, Gary A ^b   Thijs, Vincent N S ^c,d  

^a ASKLEPIOS KLINIK ALTONA   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Desmoteplase; Ischaemic stroke; Tenecteplase; Thrombolytics

Indexed keywords

ALFIMEPRASE; ALTEPLASE; DESMOTEPLASE; DEXTRAN SULFATE; FIBRIN; FIBRINOKINASE; FIBRINOLYTIC AGENT; LANOTEPLASE; MONTEPLASE; PAMITEPLASE; PLACEBO; PLASMIN; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; BRAIN ANGIOGRAPHY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; NATIONAL HEALTH ORGANIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; RISK BENEFIT ANALYSIS;

ANIMALS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84876457391     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000348705     Document Type: Review

References (82)

1. Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. Lancet 2008; 371: 1612-1623.
2. Collen D, Lijnen HR: Thrombolytic agents. Thromb Haemost 2005; 93: 627-630.
3. Rijken DC, Collen D: Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041.
4. Collen D, Lijnen HR: Tissue-type plasminogen activator: A historical perspective and personal account. J Thromb Haemost 2004; 2: 541-546.
5. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
6. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al: Stroke: Working toward a prioritized world agenda. Cerebrovasc Dis 2010; 30: 127-147.
7. Kaste M: Stroke: Advances in thrombolysis. Lancet Neurol 2013; 12: 2-4.
8. Tillett WS, Garner RL: The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
9. Ouriel K: A history of thrombolytic therapy. J Endovasc Ther 2004; 11(suppl 2):II128-II133.
10. Sikri N, Bardia A: A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34: 318-327.
11. Tillett WS, Johnson AJ, McCarty WR: The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955; 34: 169-185.
12. Macfarlane RG, Pilling J: Fibrinolytic activity of normal urine. Nature 1947; 159: 779.
13. Lack CH: Staphylokinase: An activator of plasma protease. Nature 1948; 161: 559.
14. Sussman BJ, Fitch TS: Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167: 1705-1709.
15. Fletcher AP, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, et al: A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-142.
16. Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963; 13: 927-937.
17. Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964; 189: 373.
18. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial Y Italy (MAST-I) Group. Lancet 1995; 346: 1509-1514.
19. Thrombolytic therapy with streptokinase in acute ischemic stroke: Multicenter Acute Stroke Trial Y Europe study group. N Engl J Med 1996; 335: 145-150.
20. Fujishima M, Omae T, Tanaka K, Iino K, Matsuo O, Mihara H: Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 1986; 37: 487-498.
21. Wardlaw JM, Warlow CP: Thrombolysis in acute ischemic stroke: Does it work? Stroke 1992; 23: 1826-1839.
22. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, et al: Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984; 310: 609-613.
23. Van de Werf F, Bergmann SR, Fox KA, de Geest H, Hoyng CF, Sobel BE, et al: Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610.
24. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: The GUSTO investigators. N Engl J Med 1993; 329: 673-682.
25. Terashi A, Kobayashi Y, Katayama Y, Inamura K, Kazama M, Abe T: Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost 1990; 16: 236-241.
26. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 min. Stroke 1992; 23: 632-640.
27. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 min from onset. Stroke 1992; 23: 641-645.
28. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
29. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
30. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
31. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
32. Clark WM, Albers GW, Madden KP, Hamilton S: The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276 g): Results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study investigators. Stroke 2000; 31: 811-816.
33. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
34. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al: Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
35. Shobha N, Buchan AM, Hill MD: Thrombolysis at 3-4.5 h after acute ischemic stroke onset Y evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011; 31: 223-228.
36. Parsons MW: Treating as early as possible with thrombolysis is crucial, but can we do better in the sub-4.5-hour time window? Cerebrovasc Dis 2011; 31: 229.
37. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-2948.
38. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al: Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008; 372: 1303-1309.
39. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al: Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR. Lancet Neurol 2010; 9: 866-874.
40. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al: Thrombolysis in very elderly people: Controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. Br Med J 2010; 341:c6046.
41. Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, et al: Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41: 2568-2574.
42. Mishra NK, Davis SM, Kaste M, Lees KR: Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010; 33: 2531-2537.
43. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al: The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke [the Third International Stroke Trial (IST-3)]: A randomised controlled trial. Lancet 2012; 379: 2352-2363.
44. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: The Japan Post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
45. Micieli G, Marcheselli S, Tosi PA: Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag 2009; 5: 397-409.
46. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL: T-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012; 119: 4752-4761.
47. Tsikouris JP, Tsikouris AP: A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001; 21: 207-217.
48. Molina CA: Reperfusion therapies for acute ischemic stroke: Current pharmacological and mechanical approaches. Stroke 2011; 42(suppl):S16-S19.
49. Planas AM, Traystman RJ: Advances in translational medicine 2010. Stroke 2011; 42: 283-284.
50. Schellinger PD, Kohrmann M: Current acute stroke trials and their potential impact on the therapeutic time window. Expert Rev Neurother 2012; 12: 169-177.
51. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Assoc 1999; 282: 2003-2011.
52. Medcalf RL, Davis SM: Plasminogen activation and thrombolysis for ischemic stroke. Int J Stroke 2012; 7: 419-425.
53. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, et al: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032-3040.
54. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM: A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36: 607-612.
55. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al: Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72: 915-921.
56. Lyden P: Tenecteplase for acute ischemic stroke. Int J Stroke 2011; 6: 509-510.
57. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al: A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099-1107.
58. Bier O: Action anticoagulante et fibrinolytique de l'extract des glands salivaires d'une chauve-souris hématophage (Desmodus rufus). C R Soc Biol (Paris) 1932; 110: 129-131.
59. Kratzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, et al: The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: Cloning and expression. Gene 1991; 105: 229-237.
60. Medcalf RL: Desmoteplase: Discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012; 165: 75-89.
61. Paciaroni M, Medeiros E, Bogousslavsky J: Desmoteplase. Expert Opin Biol Ther 2009; 9: 773-778.
62. Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, et al: Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-25603.
63. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 h after stroke onset. Stroke 2006; 37: 1227-1231.
64. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
65. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al: Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.
66. Fiebach JB, Al-Rawi Y, Wintermark M, Furlan AJ, Rowley HA, Lindsten A, et al: Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012; 43: 1561-1566.
67. Von Kummer R, Albers GW, Mori E: The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke 2012; 7: 589-596.
68. Saver JL. Time is brain Y quantified. Stroke 2006; 37: 263-266.
69. Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ, Ford GA: Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003; 34: 71-76.
70. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al: The 'golden hour' and acute brain ischemia: Presenting features and lytic therapy in >30,000 patients arriving within 60 min of stroke onset. Stroke 2010; 41: 1431-1439.
71. Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW: How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011; 7: 400-409.
72. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M: Reducing inhospital delay to 20 min in stroke thrombolysis. Neurology 2012; 79: 306-313.
73. Baron JC, von Kummer R, del Zoppo GJ: Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219-2221.
74. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, et al: Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 h. Stroke 2002; 33: 2438-2445.
75. Muir KW, Buchan A, von Kummer R, Rother J, Baron JC: Imaging of acute stroke. Lancet Neurol 2006; 5: 755-768.
76. Gralla J, Brekenfeld C, Mordasini P, Schroth G: Mechanical thrombolysis and stenting in acute ischemic stroke. Stroke 2012; 43: 280-285.
77. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al: Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241-1249.
78. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al: Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60: 508-517.
79. Sandercock P, Wardlaw J, Lindley R: Where are we now with intravenous thrombolysis for acute ischaemic stroke? Int J Stroke 2010; 5: 381-382.
80. Wang Y, Liao X, Zhao X, Wang C, Liu L, Zhou Y, et al: Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II). Int J Stroke 2009; 4: 49-53.
81. Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, et al: A multicentre, randomized, double-blinded, placebocontrolled phase III study to investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7: 74-80.
82. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al: Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet 2012; 379: 2364-2372.